Condition: Stage III NSCLC · Sponsor: Intergroupe Francophone de Cancerologie Thoracique
The use of neoadjuvant immuno-chemotherapy could improve survival outcomes of patients eligible for sequential radio-chemotherapy comparing to the benefit already obtained with maintenance immunotherapy.
This description comes directly from the study's public registry record.
Contact IFCT · +33 1.56.81.10.45 · contact@ifct.fr
Always discuss trial participation with your own doctor first.
| Angers - Centre Paul Papin | Angers, France | Recruiting |
| Angers - CHU | Angers, France | Recruiting |
| Avignon - CH | Avignon, France | Recruiting |
| Boulogne - Ambroise Paré | Boulogne, France | Recruiting |
| Brest - CHU | Brest, France | Recruiting |
| Caen - CHU | Caen, France | Recruiting |
| Caen - CRLCC | Caen, France | Recruiting |
| Créteil - CHI | Créteil, France | Recruiting |
| Dijon - CRLCC | Dijon, France | Recruiting |
| Le Mans - CHG | Le Mans, France | Recruiting |
| Lille - CRLCC | Lille, France | Recruiting |
| Marseille - APHM | Marseille, France | Recruiting |
+ 13 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06656598